All In Biotech

NDA 019777 · Twi Pharms

Zestril

Lisinopril · Oral

Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

May 19, 1988

Approved uses

5

Original approval plus efficacy supplements

Registered trials

140

25 Phase 3, 10 recruiting

FAERS reports

307,269

186,997 serious, 25,491 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ZESTRIL as soon as possible [see Warnings and Precautions ( 5.1 )]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Zestril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

What it is approved for

From the label in effect Jan 2, 2025.

Zestril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Zestril is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also...

Mechanism: Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • ZESTRIL · LISINOPRIL 20MG · TABLET, ORAL · Prescription · TE AB
  • ZESTRIL · LISINOPRIL 5MG · TABLET, ORAL · Prescription · TE AB
  • ZESTRIL · LISINOPRIL 30MG · TABLET, ORAL · Prescription · TE AB
  • ZESTRIL · LISINOPRIL 40MG · TABLET, ORAL · Prescription · TE AB
  • ZESTRIL · LISINOPRIL 10MG · TABLET, ORAL · Prescription · TE AB
  • ZESTRIL · LISINOPRIL 2.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lisinopril" as an intervention, any sponsor and status, largest first.

All 140 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue20,139
  • nausea18,701
  • drug ineffective17,858
  • diarrhoea17,531
  • dyspnoea14,122
  • pain13,788
  • dizziness13,716
  • headache13,187
  • off label use11,262
  • vomiting11,193
  • asthenia11,051
  • arthralgia9,780

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,531
20054,429
20064,749
20074,668
20085,695
20097,749
201010,965
201111,262
201213,038
201312,466
201417,956
201522,223
201622,908
201721,645
201823,498
201922,728
202018,102
202115,726
202215,254
202313,279
202412,698
202513,641
20269,056

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zestril (Lisinopril)

2024 spending

$3.1M

Beneficiaries

796

2,794 claims

Per beneficiary

$3,903

$12.56 per unit

View as table
YearSpending
2020$5,757,754
2021$5,279,666
2022$4,881,184
2023$4,012,065
2024$3,106,440

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 727 on PubMed

Sponsor: Twi Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.